Xencor (NASDAQ:XNCR) Shares Down 5.4% – What’s Next?

Xencor, Inc. (NASDAQ:XNCR) fell 5.4% during mid-day trading on Tuesday . The stock traded as low as $8.21 and last traded at $7.92. 107,457 shares were traded during trading, a decline of 82% from the average session volume of 604,578 shares. The stock had previously closed at $8.37.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on XNCR shares. Wells Fargo & Company dropped their target price on shares of Xencor from $37.00 to $33.00 and set an “overweight” rating on the stock in a report on Friday, February 28th. StockNews.com lowered Xencor from a “hold” rating to a “sell” rating in a research note on Friday, March 14th. One equities research analyst has rated the stock with a sell rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $34.38.

Xencor Trading Down 7.9 %

The company has a debt-to-equity ratio of 0.01, a current ratio of 6.23 and a quick ratio of 6.23. The firm has a market cap of $543.26 million, a P/E ratio of -2.41 and a beta of 0.90. The company’s 50 day moving average is $14.29 and its two-hundred day moving average is $19.59.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, topping the consensus estimate of ($0.81) by $0.19. The company had revenue of $52.79 million for the quarter, compared to analyst estimates of $17.14 million. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. On average, sell-side analysts predict that Xencor, Inc. will post -3.68 earnings per share for the current year.

Hedge Funds Weigh In On Xencor

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Sterling Capital Management LLC raised its position in Xencor by 732.4% in the fourth quarter. Sterling Capital Management LLC now owns 1,182 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 1,040 shares in the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of Xencor in the 4th quarter valued at approximately $34,000. GAMMA Investing LLC boosted its stake in Xencor by 31.0% in the 4th quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company’s stock valued at $49,000 after buying an additional 508 shares in the last quarter. Quarry LP grew its position in Xencor by 111.4% in the third quarter. Quarry LP now owns 4,000 shares of the biopharmaceutical company’s stock valued at $80,000 after acquiring an additional 2,108 shares during the period. Finally, KBC Group NV raised its stake in Xencor by 26.0% during the fourth quarter. KBC Group NV now owns 3,936 shares of the biopharmaceutical company’s stock worth $90,000 after acquiring an additional 813 shares in the last quarter.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.